MX2022003466A - Interrupción de los tejidos tumorales al dirigir la proteína de activación de fibroblastos (fap). - Google Patents
Interrupción de los tejidos tumorales al dirigir la proteína de activación de fibroblastos (fap).Info
- Publication number
- MX2022003466A MX2022003466A MX2022003466A MX2022003466A MX2022003466A MX 2022003466 A MX2022003466 A MX 2022003466A MX 2022003466 A MX2022003466 A MX 2022003466A MX 2022003466 A MX2022003466 A MX 2022003466A MX 2022003466 A MX2022003466 A MX 2022003466A
- Authority
- MX
- Mexico
- Prior art keywords
- fap
- activation protein
- fibroblast activation
- tumor tissues
- targeting fibroblast
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000004913 activation Effects 0.000 title abstract 2
- 210000002950 fibroblast Anatomy 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 241000282465 Canis Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a composiciones y métodos que comprenden un receptor de antígeno quimérico (CAR) capaz de unirse a la proteína de activación de fibroblastos (FAP) para usarse en el tratamiento de enfermedades, trastornos o afecciones asociadas con la expresión de FAP en células asociadas a tumores caninos, de ratón o humanos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962904340P | 2019-09-23 | 2019-09-23 | |
PCT/US2020/052227 WO2021061778A1 (en) | 2019-09-23 | 2020-09-23 | Disrupting tumor tissues by targeting fibroblast activation protein (fap) |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022003466A true MX2022003466A (es) | 2022-09-07 |
Family
ID=74881688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022003466A MX2022003466A (es) | 2019-09-23 | 2020-09-23 | Interrupción de los tejidos tumorales al dirigir la proteína de activación de fibroblastos (fap). |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210087295A1 (es) |
EP (1) | EP4034554A4 (es) |
JP (1) | JP2022548778A (es) |
KR (1) | KR20220066312A (es) |
CN (1) | CN114746438A (es) |
AU (1) | AU2020353000A1 (es) |
BR (1) | BR112022005423A2 (es) |
CA (1) | CA3151550A1 (es) |
IL (1) | IL291342A (es) |
MX (1) | MX2022003466A (es) |
WO (1) | WO2021061778A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019067425A1 (en) | 2017-09-26 | 2019-04-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISEASE BY REDIRECTED T-CELL IMMUNOTHERAPIES |
CA3218475A1 (en) * | 2021-05-21 | 2022-11-24 | Shipra DAS | Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors |
WO2023245074A2 (en) * | 2022-06-14 | 2023-12-21 | Purdue Research Foundation | Car-expressing pluripotent stem cell-derived neutrophils loaded with drug nanoparticles and uses thereof |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2347833A1 (en) * | 1998-11-18 | 2000-05-25 | Genentech, Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
DE60140252D1 (de) * | 2000-06-22 | 2009-12-03 | Genentech Inc | Agonistische monoklonale antikörper gegen trkc |
CA2533593A1 (en) * | 2003-07-26 | 2005-02-10 | Biogen Idec Ma Inc. | Altered antibodies having improved antigen-binding affinity |
CN101952317B (zh) * | 2008-01-24 | 2015-07-22 | 诺沃-诺迪斯克有限公司 | 人化抗-人nkg2a单克隆抗体 |
EP2756521A4 (en) * | 2011-09-16 | 2015-04-22 | Univ Pennsylvania | RNA-MANIPULATED T-CELLS FOR THE TREATMENT OF CANCER |
AR092745A1 (es) * | 2012-10-01 | 2015-04-29 | Univ Pennsylvania | Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer |
MX2016002547A (es) * | 2013-08-28 | 2016-06-17 | Stemcentrx Inc | Metodos de conjugacion de anticuerpos especificos de sitio y composiciones. |
CA2921639A1 (en) * | 2013-09-05 | 2015-03-12 | Aduro Biotech Holdings, Europe B.V. | Cd70-binding peptides and method, process and use relating thereto |
KR20180104036A (ko) * | 2016-01-22 | 2018-09-19 | 머크 샤프 앤드 돔 코포레이션 | 항-응고 인자 xi 항체 |
SI3443096T1 (sl) * | 2016-04-15 | 2023-07-31 | Novartis Ag | Sestavki in postopki za selektivno izražanje himerni antigenskih receptorjev |
JP2018035137A (ja) * | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | 新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用 |
CN107663240B (zh) * | 2016-07-29 | 2021-01-12 | 中国人民解放军第四军医大学 | 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |
CN109796532A (zh) * | 2017-11-17 | 2019-05-24 | 科济生物医药(上海)有限公司 | 靶向成纤维激活蛋白α的结合单元及其应用 |
CA3084553A1 (en) * | 2017-12-22 | 2019-06-27 | Bluebird Bio, Inc. | Multivalent chimeric antigen receptor |
-
2020
- 2020-09-23 JP JP2022518209A patent/JP2022548778A/ja active Pending
- 2020-09-23 BR BR112022005423A patent/BR112022005423A2/pt unknown
- 2020-09-23 WO PCT/US2020/052227 patent/WO2021061778A1/en unknown
- 2020-09-23 EP EP20870352.0A patent/EP4034554A4/en active Pending
- 2020-09-23 AU AU2020353000A patent/AU2020353000A1/en active Pending
- 2020-09-23 CN CN202080079493.6A patent/CN114746438A/zh active Pending
- 2020-09-23 CA CA3151550A patent/CA3151550A1/en active Pending
- 2020-09-23 MX MX2022003466A patent/MX2022003466A/es unknown
- 2020-09-23 KR KR1020227012360A patent/KR20220066312A/ko unknown
- 2020-09-23 US US17/029,702 patent/US20210087295A1/en active Pending
-
2022
- 2022-03-14 IL IL291342A patent/IL291342A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL291342A (en) | 2022-05-01 |
JP2022548778A (ja) | 2022-11-21 |
CN114746438A (zh) | 2022-07-12 |
KR20220066312A (ko) | 2022-05-24 |
AU2020353000A1 (en) | 2022-04-07 |
US20210087295A1 (en) | 2021-03-25 |
EP4034554A1 (en) | 2022-08-03 |
WO2021061778A1 (en) | 2021-04-01 |
CA3151550A1 (en) | 2021-04-01 |
EP4034554A4 (en) | 2023-10-25 |
BR112022005423A2 (pt) | 2022-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022003466A (es) | Interrupción de los tejidos tumorales al dirigir la proteína de activación de fibroblastos (fap). | |
PH12020551160A1 (en) | Chimeric antigen receptors targeting cd70 | |
MX2020012927A (es) | Diversos dominios de enlace de antigenos, nuevas plataformas y otras mejoras para terapia celular. | |
MX2019001469A (es) | Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2. | |
WO2018236870A3 (en) | METHODS AND COMPOSITIONS FOR TARGETING CANCER CELLS WITH A CHIMERIC ANTIGENIC RECEPTOR | |
PH12019500750A1 (en) | Chimeric antigen receptors for the treatment of cancer | |
AU2018291128A1 (en) | Anti-B-cell maturation antigen chimeric antigen receptors with human domains | |
MY159837A (en) | Therapeutic dll4 binding proteins | |
EP3593812A3 (en) | Treatment of cancer using chimeric antigen receptor | |
MX2019006598A (es) | Celulas asesinas naturales modificadas geneticamente y sus usos. | |
ZA201605657B (en) | Treatment of cancer using anti-cd19 chimeric antigen receptor | |
WO2007092939A8 (en) | Antigenic gm-csf peptides and antibodies to gm-csf | |
MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
MX338151B (es) | Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico. | |
PH12019502637A1 (en) | Chimeric antigen receptors targeting flt3 | |
MX2021012335A (es) | Anticuerpos humanos que se unen a ret y metodos de uso de los mismos. | |
MX2021015337A (es) | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3. | |
PH12020551447A1 (en) | Antibodies | |
MX2021002605A (es) | Anticuerpos anti-cxcl13 para el tratamiento de enfermedades autoinmunes y cancer. | |
MX2022002682A (es) | Anticuerpos anti-cd73. | |
MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
WO2018138032A3 (en) | NKp46 BINDING AGENTS | |
WO2019112978A3 (en) | Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof | |
MX2022005816A (es) | Terapia de tumores solidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70. | |
MX2021012160A (es) | Anticuerpos antiintegrina y usos de los mismos. |